Patient Resources
Indications - Entresto
ENTRESTO ® is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. ENTRESTO is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic...
Twitter Linkedin Facebook Pinterest Google plusReimbursement / eHealth - Entresto
Entresto ® is reimbursed for the treatment of adult patients with chronic heart failure with reduced ejection fraction in Belgium.
Twitter Linkedin Facebook Pinterest Google plusIndication - Kisqali
Early breast cancer
Kisqali® in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile - Kisqali mBC
As with every medicine, when using Kisqali, side effects can occur. In the case of serious or unacceptable side effects, it is possible that a dose adjustment is necessary. Here you can read more about the side effects of Kisqali.Twitter Linkedin Facebook Pinterest Google plusEfficacy - Kisqali mBC
The efficacy of Kisqali has been investigated in various studies. The following pictures summarize all the main data’s from the MONALEESA 2, 3, 7 studiesTwitter Linkedin Facebook Pinterest Google plusDosing - Kisqali mBC
4 week dosing schedule 1 INITIAL DOSING: 600 mg/day (3 tablets of 200 mg) KISQALI in combination with a NSAI Please refer to the Summary of Product Characteristics (SmPC) of the aromatase inhibitor for...Twitter Linkedin Facebook Pinterest Google plusReimbursement - Kisqali mBC
Kisqali ® is reimbursed in Belgium, you can find the reimbursement conditions on the INAMI website .
E-HealthYou can request reimbursement by...
Twitter Linkedin Facebook Pinterest Google plusPatient Resources - Kisqali mBC
×